BioPhorum CGT Regulatory Strategy workstream members provide feedback on the FDA draft guidance on considerations for the development of CAR-T cell products .
FDA draft guidance
Viewing related articles
read more
Feedback on FDA draft guidance on human gene therapy products incorporating human genome editingÂ
Jun 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
BioPhorum CGT Regulatory Strategy workstream provided feedback on FDA draft guidance on human gene therapy products incorporating human genome editing .
Feedback on FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Dec 2021 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
BioPhorum members provide feedback on FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial.